Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819632 | 0.93 | HCAR2 (0.44) | FFAR1POLBHCAR2LMNAKMT2A | |
| Butane SCHEMBL4824910 | 0.84 | POLB (0.42) | POLBLMNAKMT2AMEN1 | |
| Butane SCHEMBL23346235 | 0.82 | POLB (0.45) | POLBLMNAKMT2A | |
| SCHEMBL28980059 | 0.77 | HCAR2 (0.43) | FFAR1HCAR2LMNAKMT2A | |
| SCHEMBL2819629 | 0.77 | HCAR2 (0.43) | FFAR1HCAR2LMNAKMT2A | |
| SCHEMBL28980079 | 0.76 | LMNA (0.44) | POLBLMNAKMT2AMEN1TRPA1 | |
| SCHEMBL15898694 | 0.75 | POLB (0.43) | POLBLMNAPPARGPPARA | |
| SCHEMBL28980086 | 0.74 | ADRB2 (0.42) | POLBKMT2AMEN1 | |
| SCHEMBL27850458 | 0.74 | HTT (0.34) | LMNAKMT2AMEN1 | |
| SCHEMBL767298 | 0.72 | ESR1 (0.40) | POLBLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545583-B1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | VERSUM MAT US LLC (US) | 2020-05-13 | — | — | EP | claimed |
| US-8906774-B2 | Methods and compositions for doping silicon substrates with molecular monolayers | DYNALOY, LLC (US) | 2014-12-09 | — | — | US | claimed |
| EP-2545583-A1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | Dynaloy, LLC (US) | 2013-01-16 | — | — | EP | claimed |
| US-20120003826-A1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | VERSUM MATERIALS US, LLC | 2012-01-05 | — | — | US | claimed |
| WO-2011112546-A1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | DYNALOY, LLC (US) | 2011-09-15 | — | — | WO | claimed |
| CN-113845754-B | Preparation method of epoxy resin electronic and electric insulating material | 广东博汇新材料科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113817291-B | Carbon fiber vacuum infusion epoxy resin | 广东博汇新材料科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113845754-A | Preparation method of epoxy resin electronic and electric insulating material | 广东博汇新材料科技股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-113817291-A | Carbon fiber vacuum infusion epoxy resin | 广东博汇新材料科技股份有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-2545583-B1 | METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS | VERSUM MAT US LLC (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-2321287-B1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-8906774-B2 | Methods and compositions for doping silicon substrates with molecular monolayers | DYNALOY, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2321287-A1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010010014-A1 | 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029589-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | FFAR1 116/4885POLB 2084/4885HCAR2 250/4885 |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | FFAR1 55/4885POLB 3079/4885HCAR2 109/4885 |
| US-20100041686-A1 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES | NPY5R, NPY1R, NPY4R | FFAR1 116/4885POLB 2084/4885HCAR2 250/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | FFAR1 55/4885POLB 3079/4885HCAR2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.